Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)

Re­cur­sion ac­quires two AI-based drug dis­cov­ery com­pa­nies in $87.5M deal

AI drug de­vel­op­er Re­cur­sion Phar­ma­ceu­ti­cals has brought two more AI-fo­cused com­pa­nies with their own dis­cov­ery plat­forms un­der its wing in an ac­qui­si­tion worth $87.5 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.